

Venovo™ Venous Stent System

Proven Results In Post-Thrombotic and
Non-Thrombotic Lesions¹





Venovo™

Venous Stent System

Designed for Veins™

The iliac and femoral veins have unique challenges that must be addressed to reduce venous hypertension due to occlusive disease:


- Large caliber
- Diffuse and focal lesions
- Extrinsic compression
- Post-thrombotic change
- Complex curvature

The Venovo™ Venous Stent was designed and developed for the iliofemoral veins in collaboration with clinicians. It offers radial force, crush resistance, and flexibility without compromising on delivery accuracy and is available in the sizes needed for the iliofemoral veins.

Placement Accuracy

The Venovo™ Venous Stent System is designed to provide accurate deployment for **optimal stent placement** and lesion coverage.

100% DEPLOYMENT ACCURACY
In the VERNACULAR Study (n=170)¹




Full Range of Sizes

The Venovo™ Venous Stent provides the **broadest size range** of stents indicated for iliofemoral venous obstruction in the U.S.⁴


Stent Diameter (mm)	Stent Length (mm)						
	40	60	80	100	120	140	160
10	8F						
12	8F						
14	9F						
16	10F						
18	10F						
20	10F						

Purpose-Built Venous Stent

The Venovo™ Venous Stent was designed to treat non-thrombotic and post-thrombotic iliofemoral lesions with a balance between radial strength, compression resistance, and flexibility.




Unique 3 mm flared ends designed to **reduce stent migration** and maximize wall apposition




Compression of stent with 50 gram weight


Designed for use in **high compression** iliofemoral venous obstructions



Open-cell, **flexible design** to conform to vessel curvature while maintaining lumen diameter



Demonstrated **highest radial force** of iliofemoral venous stents in the U.S.²



Tantalum markers for best-in-class **visibility** under fluoroscopy⁴



Proven Safe and Effective

VERNACULAR Study Design	Prospective, multi-center, non-randomized, single-arm; Core lab & DSMB	
Purpose	To assess the safety and effectiveness of the Venovo™ Venous Stent for the treatment of iliofemoral occlusive disease.	
As Treated Population	170 subjects at 21 sites in the U.S., Europe, and Australia/NZ	
Primary Endpoint*	· Primary patency*(12 months)	· Freedom from MAE (30 days)
Secondary Endpoints	· VCSS Pain Score/QoL assessment at 30 days, 6 and 12 months	· Freedom from TVR/TLR at 30 days, 6 and 12 months
	· Procedure/technical success at index procedure	· X-ray analysis of stent fracture at 12 months

* Evaluated against literature derived performance goal of 74% for efficacy (p<.0001) and 89% for safety (p=.032)

96.9%

PRIMARY PATENCY IN
NON-THROMBOTIC LESIONS
at 12 months¹

81.3%

PRIMARY PATENCY IN
POST-THROMBOTIC LESIONS
at 12 months¹


ZERO

STENT
FRACTURES
at 12 months¹

Weighted Primary Patency 88.3%

Patient-Reported Improvements

In the VERNACULAR Clinical Study, the Venovo™ Venous Stent demonstrated **significant improvement** in VCSS pain scores and quality of life (CIVIQ-20) compared to baseline at 12 months.¹



PTS = Post-Thrombotic Syndrome NIVL = Non-Thrombotic Iliac Vein Lesion

Venovo™

Venous Stent System

Venovo™ Venous Stent System Product Codes

Diameter (mm)	Length (cm)	Sheath Size (Fr)	80 cm Catheter Length	120 cm Catheter Length	Diameter (mm)	Length (cm)	Sheath Size (Fr)	80 cm Catheter Length	120 cm Catheter Length
10	40	8	☐ VENEM10040	☐ VENEL10040	16	40	10	☐ VENEM16040	☐ VENEL16040
	60	8	☐ VENEM10060	☐ VENEL10060		60	10	☐ VENEM16060	☐ VENEL16060
	80	8	☐ VENEM10080	☐ VENEL10080		80	10	☐ VENEM16080	☐ VENEL16080
	100	8	☐ VENEM10100	☐ VENEL10100		100	10	☐ VENEM16100	☐ VENEL16100
	120	8	☐ VENEM10120	☐ VENEL10120		120	10	☐ VENEM16120	☐ VENEL16120
	140	8	☐ VENEM10140	☐ VENEL10140		140	10	☐ VENEM16140	☐ VENEL16140
	160	8	☐ VENEM10160	☐ VENEL10160		160	10	☐ VENEM16160	☐ VENEL16160
12	40	8	☐ VENEM12040	☐ VENEL12040	18	40	10	☐ VENEM18040	☐ VENEL18040
	60	8	☐ VENEM12060	☐ VENEL12060		60	10	☐ VENEM18060	☐ VENEL18060
	80	8	☐ VENEM12080	☐ VENEL12080		80	10	☐ VENEM18080	☐ VENEL18080
	100	8	☐ VENEM12100	☐ VENEL12100		100	10	☐ VENEM18100	☐ VENEL18100
	120	8	☐ VENEM12120	☐ VENEL12120		120	10	☐ VENEM18120	☐ VENEL18120
	140	8	☐ VENEM12140	☐ VENEL12140		140	10	☐ VENEM18140	☐ VENEL18140
	160	8	☐ VENEM12160	☐ VENEL12160		160	10	☐ VENEM18160	☐ VENEL18160
14	40	9	☐ VENEM14040	☐ VENEL14040	20	40	10	☐ VENEM20040	☐ VENEL20040
	60	9	☐ VENEM14060	☐ VENEL14060		60	10	☐ VENEM20060	☐ VENEL20060
	80	9	☐ VENEM14080	☐ VENEL14080		80	10	☐ VENEM20080	☐ VENEL20080
	100	9	☐ VENEM14100	☐ VENEL14100		100	10	☐ VENEM20100	☐ VENEL20100
	120	9	☐ VENEM14120	☐ VENEL14120		120	10	☐ VENEM20120	☐ VENEL20120
	140	9	☐ VENEM14140	☐ VENEL14140		140	10	☐ VENEM20140	☐ VENEL20140
	160	9	☐ VENEM14160	☐ VENEL14160		160	10	☐ VENEM20160	☐ VENEL20160

¹ The Venovo™ Venous Stent System was studied in the global VERNACULAR clinical trial, which was a prospective, multi-center, non-randomized, single-arm study of 170 patients. The primary effectiveness endpoint of the study was primary patency (PP) at 12 months post-index procedure. Patients who received a Venovo™ Venous Stent had a weighted PP rate of 88.3%, demonstrating a statistically significant difference from a literature-derived performance goal (PG) of 74%, with an 81.3% PP rate for subjects with post-thrombotic syndrome and 96.9% PP rate for subjects with non-thrombotic iliac vein lesions. The primary safety endpoint was freedom from major adverse events (MAE) through 30 days post-index procedure. Freedom from MAE was 93.5%, demonstrating a statistically significant difference from a literature-derived PG of 89%. Secondary endpoints included acute technical success, Quality of Life (QoL) assessment, Venous Clinical Severity Score (VCSS – Pain score) and stent fractures. Results demonstrated 100% acute technical success, defined as successful deployment of stent(s) to intended target with adequate lesion coverage as assessed by the Investigator at the time of the index procedure. At the 12-month follow-up, the CIVIQ-20 assessment demonstrated a change from baseline in the total study population of -15.7 with 95% confidence interval of -18.41 to -12.96 (P <.0001) and, for the VCSS Pain score, a change from baseline in the total population of -1.7 with a 95% confidence interval of -1.81 to -1.49 (P <.0001). Stents were evaluated at the 12-month follow-up for fracture analysis. An anteroposterior and lateral x-ray for each evaluated stent were sent to an independent core lab for analysis. 137 subjects' x-rays were analyzed and no stent fractures were reported. Missing x-ray analyses were recorded as protocol deviations. VERNACULAR Clinical Study. Data on File. Bard Peripheral Vascular, Inc., Tempe, AZ.

² Results shown in bench testing are based on data averages (n=6, 14 mm x 90-120 mm stents). Data on file, Bard Peripheral Vascular, Tempe, AZ. Bench tests may not be indicative of clinical performance. Different test methods may yield different results. As of April 2019. U.S. only.

³ Results shown in bench testing. Average foreshortening = 2.9% (values based on mathematical calculations). Data on file, Bard Peripheral Vascular, Inc., Tempe, AZ. Bench tests may not be indicative of clinical performance. Different test methods may yield different results.

⁴ As of April 2019.

Venovo™ Venous Stent System

Indications for Use: The Venovo™ Venous Stent System is indicated for the treatment of symptomatic iliofemoral venous outflow obstruction. **Contraindications:** The Venovo™ Venous Stent System is contraindicated for use in patients with a known hypersensitivity to nitinol (nickel-titanium) and tantalum, who cannot receive intraprocedural anti-coagulation therapy, or who are judged to have a lesion that prevents complete inflation of a balloon dilatation catheter or proper placement of the stent or the stent delivery system. **Warnings:** The Venovo™ Venous Stent System is supplied sterile and is intended for single use only. Do not resterilize and/or reuse the device. Do not use in patients with total venous occlusion that cannot be dilated to allow passage of the guidewire. Do not use the device with contralateral access. Do not use if pouch is opened or damaged. Do not use the device after the "Use By" date specified on the label. Persons with allergic reactions to nitinol (nickel-titanium) alloy and/or tantalum may suffer an allergic response to this implant. Do not expose the delivery system to organic solvents, e.g., alcohol. The stent is not designed for repositioning or recapturing. Stenting across a major branch could cause difficulties during future diagnostic or therapeutic procedures. If a long lesion needs to be stented consider using the longest available stent rather than overlapping stents. If multiple stents are placed in an overlapping fashion, they should be of similar composition (i.e., nitinol). The long-term outcomes following repeat dilatation of endothelialized stents are unknown. The safety and effectiveness of this device for use in the arterial system have not been established. **Precautions:** The device is intended for use by physicians who have received appropriate training. During system flushing, observe that saline exits at the catheter tip. The delivery system is not designed for use with power injection systems. Recrossing a partially or fully deployed stent with adjunct devices must be performed with caution. Prior to stent deployment, remove slack from the delivery system catheter outside the patient. If excessive force is felt during stent deployment, do not force the delivery system. Remove the delivery system and replace with a new unit. Store in a cool, dark, dry place. Do not attempt to break, damage, or disrupt the stent after placement. **Potential Adverse Events:** Allergic/anaphylactic reaction · Amputation · Aneurysm · Arteriovenous fistula · Death related/unrelated to procedure · Dissection · Embolization · Extravasation · Fever · Hemorrhage/bleeding requiring a blood transfusion · Hematoma · Hypotension/hypertension · Incorrect positioning of the stent requiring further stenting or surgery · Intimal injury/dissection · Ischemia/infarction of tissue/organ · Local infection · Malposition (failure to deliver the stent to the intended site) · Open surgical repair · Pain · Pulmonary embolism · Pseudoaneurysm · Renal failure · Respiratory arrest · Restenosis · Rupture · Septicemia/bacteremia · Stent Fracture · Stent Migration · Vasospasm · Venous occlusion/thrombosis/restenosis **Please consult package insert for all indications, contraindications, hazards, warnings, precautions, and information for use.** BD, the BD logo, Bard, Designed for Veins, and Venovo are trademarks of Becton, Dickinson and Company or its affiliates. © 2019 BD. All rights reserved. Illustrations by Mike Austin. Copyright © 2019. All rights reserved. Bard Peripheral Vascular, Inc. | www.bardpv.com | 1 800 321 4254 | 1625 W. 3rd Street Tempe, AZ 85281 BPV/VEDI/0119/0039

벡톤디킨슨코리아(주)
서울특별시 강남구 테헤란로 142, 16층

bd.com

